Sareum is an experienced and specialist Structure-based Drug Discovery company. We accelerate and improve the productivity of both our in-house and our partners' discovery research using our proprietary approaches.

Sareum has a highly experienced team with a track record of delivering high quality results for pharmaceutical and biotechnology clients.

Sareum is developing a robust pipeline of novel cancer drug candidates for partnering with pharmaceutical companies. We generate revenues to support this pipeline through the provision of our specialist discovery research services.

Sareum delivers results through the entire drug discovery value chain, from gene through to valuable preclinical candidate. We carry out complete structure-based discovery programmes for creating novel pre-clinical candidates as well as specific tailored projects to resolve clients' issues in gene to structure, structure to lead, and/or lead to candidate activities.

Sareum creates novel IP and highly valuable clinical candidates for our clients across a range of therapeutic areas. We are very flexible in our approach to how we structure our partnerships and can engage in fee-for-service, out-source research, technology transfer or joint research programmes.

Sareum is a public listed company and its shares are listed on the AIM market of the London Stock Exchange.

For immediate release 15 November 2007


SAREUM HOLDINGS PLC
("Sareum" or "the Company")

AGM Statement


At the Company's annual general meeting held today, the following resolutions
were passed unanimously by shareholders on a show of hands.


The proxy votes received prior to the meeting on each resolution were as
follows:

ORDINARY RESOLUTIONS Votes Discretion Votes Votes
For Against Withheld

1.To receive and adopt the
Directors' report
and financial statements for the year 8,724,070 221,058 0 0
ended 30 June 2007. 97.53% 2.47% 0% 0%


2. To receive and adopt the
Remuneration
Committee report for the year ended 8,679,070 266,058 0 0
30 June 2007. 7.03% 2.97% 0% 0%


3.To re-elect Dr Paul Harper 8,724,070 221,058 0 0
as Director. 97.53% 2.47% 0% 0%


4.To re-elect Mr Giorgio
Reggiani as 8,576,070 366,058 3,000 0
Director. 95.88% 4.09% 0.03% 0%


5.To re-appoint Shipleys LLP
as auditors and
authorise the Directors to fix their 8,721,070 221,058 3,000 0
remuneration. 97.50% 2.47% 0.03% 0%

6.To authorise Directors for the
purposes of
section 80 of the Companies Act 1985
(the
Act) to allot relevant securities
(within 8,531,070 366,058 48,000 0
the meaning of that section) up to an 95.37% 4.09% 0.54% 0%
aggregate nominal amount of 90,000.



SPECIAL RESOLUTIONS Votes Discretion Votes Votes
For Against Withheld
7.Subject to the passing of resolution
6, to
authorise Directors, in accordance
with
section 95 of the Act, to allot
equity
securities (as defined in section 94
of
the Act) wholly for cash up to an 8,531,070 321,058 93,000 0
aggregate nominal amount of 50,000. 95.37% 3.59% 1.04% 0%


8.To authorise the Company to send or
supply
documents or information to
shareholders
by making them available on the 8,549,070 266,058 130,000 0
Company's 95.58% 2.97% 1.45% 0%
website or other electronic means.

For further information please contact:

Sareum Holdings +44 (0) 1223 497700

Tim Mitchell, Chief Executive Officer

Buchanan Communications +44 (0) 20 7466 5000


Tim Anderson, Mary-Jane Johnson

and 5% up today, :):)

Fernandes: the new appointment sounds good. I didn't manage to motor down to the AGM yesterday - would have been interesting.

Didn,t know that u planned to, I was at work all day so i had no chance for it

Sareum Holdings PLC
18 November 2007



Sareum Holdings plc

Director's shareholding


Sareum Holdings plc (the "Company") was informed on 16 November 2007 that on 16
November 2007 a director of the Company, Dr Alastair Riddell, purchased
1,000,000 ordinary shares of 0.025p of the Company ("Ordinary Shares") at a
price of 0.94p per Ordinary Share.

Dr Alastair Riddell now holds 1,000,000 Ordinary Shares representing 0.17 per
cent. of the Company's total voting rights.



Nice to see a bit of director confidence.

Yes indeed!

well done Mr Riddell :):)

Top Director Buys

Sareum (SAR)
Director name: Mr Alastair Riddell
Amount purchased: 1,000,000 @ 94.00p
Value: 940,000

With Market Cap 5,73 m I would say it is pretty big one....

Sareum Holdings PLC
30 November 2007

30 November 2007


Sareum Holdings plc ("Sareum" or the "Company")

Total Voting Rights

In accordance with the FSA's Disclosure and Transparency Rules, the Company
would like to notify the market of the following:

As at the date of this announcement, the Company's issued share capital consists
of 598,697,713 ordinary shares with a nominal value of 0.025p each ("Ordinary
Shares"), with voting rights. The Company does not hold any Ordinary Shares in
Treasury.

Therefore, the total number of Ordinary Shares with voting rights is
598,697,713.

The above figure of 598,697,713 Ordinary Shares may be used by shareholders in
the Company as the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change in their interest
in, the share capital of the Company under the FSA's Disclosure and Transparency
Rules.

For further information:

Sareum Holdings plc
01223 497700
Tim Mitchell, Chief Executive Officer

Buchanan Communications
020 7466 5000
Tim Anderson/Mary-Jane Johnson

Grant Thornton Corporate Finance
020 7383 5100
Philip Secrett/Colin Aaronson

I've transferred funds elsewhere for now but am keeping this on my watchlist.

A lot of these early-stage bio companies just take ages to get going properly because much of the research literally takes years. However, I'm sure they're doing some solid work - as evidenced by their partners in oncology - and will win through eventually.

Most don't Toya; Phase I to Phase III trials can take anything up to 7 years during which time the company returns to the market for cash top ups on a regular basis. Mind you if you pick the right one the return can be spectacular. Actually, I have one in my bottom drawer, CeNeS and they do have a drug at Phase III. Following numerous cash calls and a consolidation, even if the SP rockets in previously mentioned spectacular fashion, I doubt I will ever be in profit!

AZM are another good example.

Guess the trick is to get in really low and wait for a possible bit of good news, double bag, take the profit and run like the clappers.

pth

Toya, looks like your transfer was in right moment, 5% down today,

ptholden, if you will have a look at chart of Sareum, one time on year is always some news or expectations which help to make some nice profit:)

Sareum Holdings PLC
12 December 2007



For immediate release 12 December 2007



SAREUM HOLDINGS PLC
(\"Sareum\" or the \"Company\")

Extension of Genentech Agreement

Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery
business, is pleased to announce that it has extended its agreement with
Genentech, Inc. for a further 6 months following its initial agreement announced
in November 2006.

Under the terms of this agreement, Sareum will continue to apply its skills in
high throughput protein expression, purification and structure determination on
drug discovery targets designated by Genentech.

In return, Sareum will receive research fees and may receive specific
success-dependent milestone payments. Financial terms of the agreement were not
disclosed.

Commenting on the agreement, Sareum\'s Chief Executive Officer, Dr Tim Mitchell,
said: \"Successfully delivering on relationships with leading companies such as
Genentech is a key component of our business strategy and an outstanding
validation of Sareum\'s technology and expertise. We are very pleased to have
supported Genentech\'s programs over the last 12 months, and look forward to
continuing this important relationship.\"

For further information:

Sareum Holdings 01223 497700

Tim Mitchell, Chief Executive Officer

Buchanan Communications 020 7466 5000

Tim Anderson, Mary-Jane Johnson

Grant Thornton Corporate Finance 020 7383 5100

Philip Secrett, Colin Aaronson

Fernandesb: this is just an extension of an existing contract so nothing earth-shattering, hence lack of movement in sp. When they do get a new contract, though, the sp will shoot up - as it did in January; will get back in then.

Toya, my problem is that I am in already:):)

Good luck then Fernandesb - only a matter of time. Alternatively, you might consider biting the bullet and moving funds elsewhere, where your money might do better in the short term. I've only learned that recently, from people here, and it's been very helpful.

Anyone like to suggest why such a contract is ONLY for 6-months?

Just seems rather short.

Also I don't like to see Dilution ( eg in Aug06 and another? during 07), that's very damaging for earlier shareholders.

well I spoke to the bloke (nice guy Dr. Mitchell), they say they are talking to many companies, potential partners, they are part of many events around the world. He sounded very sensible to me. I believe they have right people, right goals and they know the way they should go. But as someone on BB said before, this kind of company might be even years of developing something before we hear something spectacular , I'm still in ready to add a little bit more is something happen.

Fernandes: I think you're right about the people at SAR but time is the key factor probably.

Am enjoying a very nice ride from .225 hope some of you others are on board.